Concepedia

Publication | Open Access

Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma

DOIFull Paper Access

25

Citations

27

References

2022

Year

Jiaojiao Wang, Andre R. Jordan, Huabin Zhu, Sarrah L. Hasanali, Eric F. Thomas, Soum D. Lokeshwar, Daley S. Morera, Sung Alexander, Joseph McDaniels, Anuj K. Sharma,
Cancer Cell International

Abstract

HAS3 is the first known target of SF in RCC cells. In combination with MU (human equivalent-dose, 0.6-1.1-g/day), SF targets HAS3 and effectively abrogates mRCC.

References

YearCitations

Page 1